ScholarLens Back to search
2009•Zhongguo huxi yu weizhong jianhu zazhiRequires access

Assessing the Effects of Levofloxacin Combined with Cefoperazone/Sulbactam for the Treatment of Ventilator-Associated Pneumonia

HU Zhuo-ju

Open publisher page 0 citations

Abstract

Objective To evaluate the efficacy and safety of Levofloxacin combined with Cefoperazone/Sulbactam on the patients with ventilator-associated pneumonia(VAP).Methods The clinical effect of Levofloxacin combined with Cefoperazone/Sulbactam on ventilator-associated pneumonia in 58 paitiens with VAP were retrospectively analyzed.Results 26 patients(44.8%) were cured,18 patients(31.1%) were marked improved,and 14 patients(24.1%) were ineffective.The total clinical efficacy rate was 75.9%.55 strains of bacteria were isolated,and Gram-negative bacilli were dominant pathogens(78.2%).The bacterial clearance rate was 78.2%.The prevalence of adverse reaction was 5.1%.Conclusion Levofloxacin combined with Cefoperazone/Sulbactam is effective and safe for patients with VAP.

About this research paper

What this paper is about

Objective To evaluate the efficacy and safety of Levofloxacin combined with Cefoperazone/Sulbactam on the patients with ventilator-associated pneumonia(VAP).Methods The clinical effect of Levofloxacin combined with Cefoperazone/Sulbactam on ventilator-associated pneumonia in 58 paitiens with VAP were retrospectively analyzed.Results 26 patients(44.8%) were cured,18 patients(31.1%) were marked improved,and 14 patients(24.1%) were ineffective.The total clinical efficacy rate was 75.9%.55 strains of bacteria were isolated,and Gram-negative bacilli were dominant pathogens(78.2%).The bacterial clearance rate was 78.2%.The prevalence of adverse reaction was 5.1%.Conclusion Levofloxacin combined with Cefoperazone/Sulbactam is effective and safe for patients with VAP.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To evaluate the efficacy and safety of Levofloxacin combined with Cefoperazone/Sulbactam on the patients with ventilator-associated pneumonia(VAP).Methods The clinical effect of Levofloxacin combined with Cefoperazone/Sulbactam on ventilator-associated pneumonia in 58 paitiens with VAP were retrospectively analyzed.Results 26 patients(44.8%) were cured,18 patients(31.1%) were marked improved,and 14 patients(24.1%) were ineffective.The total clinical efficacy rate was 75.9%.55 strains of bacteria were isolated,and Gram-negative bacilli were dominant pathogens(78.2%).The bacterial clearance rate was 78.2%.The prevalence of adverse reaction was 5.1%.Conclusion Levofloxacin combined with Cefoperazone/Sulbactam is effective and safe for patients with VAP.

Key concepts: Cefoperazone, Medicine, Levofloxacin, Sulbactam, Ventilator-associated pneumonia, Pneumonia, Internal medicine, Antibiotics

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Assessing the Effects of Levofloxacin Combined with Cefoperazone/Sulbactam for the Treatment of Ventilator-Associated Pneumonia — Research Paper | ScholarLens